GLS and triple-negative breast carcinoma: The CMR inhibitor CB-839 is a reversible non-competitive allosteric glutaminase (GLS) inhibitor, exhibiting anti-proliferative activity in triple-negative breast cancer cell lines, and in xenografts [12].